Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taro Rejects Sun Pharma’s Settlement Offer; Suggests Shareholder Referendum

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Israeli generic drug maker Taro has rejected Sun Pharma's proposal for a merger at a value of $9.50 per share or increase the offer price for non-promoter shares to $9 for every ordinary share. In a letter written to Sun Pharma's Chairman and Managing Director Dilip Shanghvi, Taro Chairman Barrie Levitt said the Taro board of directors "did not view the two options" set forth in the proposal as constructive or even "in the ballpark

You may also be interested in...



Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline

MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court

Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline

MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court

Sun Pharma Buys Chattem Chemicals To Augment Its Controlled Substances Business

MUMBAI - The global economic downturn is throwing up acquisition possibilities for Indian pharmaceutical companies. India's Sun Pharma has lapped up U.S. based Chattem Chemicals, a registered narcotic API importer and producer based in Chattanooga, Tenn., for an undisclosed amount

Related Content

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel